CRMD
CorMedix Inc
7.70$
-1.2%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +627.8% | -41.0% | -38.6% | +39.9% | +56.6% | +67.3% | +39.8% | -10.0% | +32.3% | +44.8% | +595.1% | |
| – | +635.6% | -41.1% | -39.2% | +40.7% | +57.2% | +64.2% | +38.0% | -10.4% | +33.4% | +44.2% | +220.4% | |
| – | +172.3% | -31.8% | +28.7% | +69.8% | -6.2% | +153.6% | +27.2% | -18.6% | +0.6% | -6.9% | +258.7% | |
| – | +715.4% | -43.0% | -40.6% | +47.1% | +61.8% | +62.6% | +41.2% | -9.8% | +28.8% | -32.0% | +189.3% | |
| – | +293.8% | -96.2% | +433.9% | -83.0% | -99.7% | +9,491.4% | +1,251.4% | -100.0% | – | – | +231.5% | |
| – | -18.7% | -55.7% | +256.4% | -27.9% | -21.0% | -57.6% | -97.9% | -100.0% | – | +260.8% | +291.0% | |
| – | -8.7% | +84.1% | +167.3% | -13.6% | -21.2% | +788.0% | +31.0% | +61.7% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | -98.4% | |
| – | – | – | – | – | – | – | – | – | – | – | +20,455.3% | |
| – | +111.2% | +32.4% | +53.0% | +121.9% | -58.0% | -12.8% | +20.9% | +13.5% | +70.8% | +186.9% | +1,130.9% | |
| – | +114.8% | +33.7% | +53.0% | +24.0% | -25.0% | -28.6% | +28.4% | +18.1% | +80.6% | +196.8% | +415.0% | |
| – | – | -97.3% | – | – | – | +5,326.6% | +11.2% | +11.1% | +11.7% | +11.5% | +762.9% | |
| – | +91.3% | -3.7% | +9.9% | +43.2% | -60.4% | +10.1% | +95.9% | -0.3% | +94.3% | -59.8% | +358.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +835.8% | -47.6% | -954.2% | – | – | – | +42.0% | -12.3% | +27.4% | +20.7% | +378.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +46.2% | +21.1% | +45.2% | +61.6% | +35.6% | +18.3% | +31.9% | +6.9% | +26.4% | +15.7% | +36.4% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.